McMillan Shakespeare Ltd (ASX: MMS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

McMillan Shakespeare Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.00 billion
P/E Ratio 11.02
Dividend Yield 10.90%
Shares Outstanding 69.64 million
Earnings per share 1.283
Dividend per share 1.56
Year To Date Return -1.82%
Earnings Yield 9.08%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • McMillan Shakespeare Ltd (ASX: MMS)
    Latest News

    a woman
    ⏸️ Investing

    Here's why Super Retail Group Ltd and McMillan Shakespeare Limited are high-yield buys

    Super Retail Group Ltd (ASX:SUL) and McMillan Shakespeare Limited (ASX:MMS) may become targets for yield-hunting investors

    Read more »

    a woman
    ⏸️ Investing

    Mcmillan Shakespeare Limited half-year earnings climb: Is it a buy?

    Mcmillan Shakespeare Limited (ASX:MMS) returns to earlier profit levels as its business shows solid recovery.

    Read more »

    a woman
    ⏸️ Investing

    Here's why Mcmillan Shakespeare Limited is a screaming buy

    Leading salary packaging company Mcmillan Shakespeare Limited (ASX:MMS) looks to be returning to earlier earnings levels, which should really boost…

    Read more »

    a woman
    ⏸️ Investing

    REA Group Limited and McMillan Shakespeare Limited: 2 stocks ready to run in 2015

    REA Group Limited (ASX:REA) and McMillan Shakespeare Limited (ASX:MMS) may make 2015 into the year of the bull for their…

    Read more »

    a woman
    ⏸️ Investing

    Woolworths Limited and McMillan Shakespeare Limited: 2 stocks to deliver in 2015

    Woolworths Limited (ASX:WOW) and McMillan Shakespeare Limited (ASX:MMS) could be offering good value now for long-term investors.

    Read more »

    a woman
    ⏸️ Investing

    3 growth stocks to power your portfolio

    Invest the Warren Buffett Way for the long term with companies like Ramsay Health Care Limited (ASX:RHC), REA Group Limited…

    Read more »

    ⏸️ Investing

    Are these 4 growth stocks in buying territory now?

    JB Hi-Fi Limited (ASX:JBH), Sonic Healthcare Limited (ASX:SHL), McMillan Shakespeare Limited (ASX:MMS) and NIB Holdings Limited (ASX:NHF) are looking cheap…

    Read more »

    ⏸️ Investing

    4 high-yield stocks to boost your dividend income

    When others are a bit fearful, it may be time to be a little greedy with Skilled Group Ltd. (ASX:SKE),…

    Read more »

    ⏸️ Investing

    6 crash-proof investments with high dividend yields

    Is a downturn coming? Here are six ideas to defend your portfolio

    Read more »

    ⏸️ Investing

    McMillan Shakespeare Limited's profit has fallen by 12%: Should you buy?

    Full year results at McMillan Shakespeare Limited (ASX:MMS) were down year-on-year, but is it still worth buying a slice of?

    Read more »

    ⏸️ Investing

    McMillan Shakespeare Limited shares climb: Have you missed all the gains?

    Profits down 10%, but a better year ahead beckons

    Read more »

    a woman
    ⏸️ Investing

    2 cheap, quality ASX companies to buy today

    Not only are these two companies high quality, they are also cheap!

    Read more »

    Frequently Asked Questions

    Yes, McMillan Shakespeare historically pays two fully franked dividends a year.

    McMillan Shakespeare generally pays its shareholder dividends in March and September.

    McMillan Shakespeare Ltd was listed on the ASX on 15 March 2004.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    12 Sep 2024 $0.7800 100.00% Final 27 Sep 2024
    07 Mar 2024 $0.7600 100.00% Interim 22 Mar 2024
    07 Sep 2023 $0.6600 100.00% Final 22 Sep 2023
    09 Mar 2023 $0.5800 100.00% Final 24 Mar 2023
    26 Oct 2022 $0.7400 100.00% Final 10 Nov 2022
    10 Mar 2022 $0.3400 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.3110 100.00% Final 24 Sep 2021
    11 Mar 2021 $0.3020 100.00% Interim 26 Mar 2021
    05 Mar 2020 $0.3400 100.00% Interim 20 Mar 2020
    28 Aug 2019 $0.4000 100.00% Final 11 Sep 2019
    07 Mar 2019 $0.3400 100.00% Interim 22 Mar 2019
    13 Sep 2018 $0.4000 100.00% Final 28 Sep 2018
    15 Mar 2018 $0.3300 100.00% Interim 29 Mar 2018
    28 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
    30 Mar 2017 $0.3100 100.00% Interim 13 Apr 2017
    29 Sep 2016 $0.3400 100.00% Final 14 Oct 2016
    31 Mar 2016 $0.2900 100.00% Interim 15 Apr 2016
    16 Sep 2010 $0.1400 100.00% Final 15 Oct 2010
    08 Mar 2006 $0.0250 100.00% Interim 29 Mar 2006
    18 Aug 2005 $0.0240 100.00% Final 16 Sep 2005

    MMS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About McMillan Shakespeare Ltd

    McMillan Shakespeare Ltd (ASX: MMS) is an employee benefits provider. Its services include salary packaging, novated leasing, disability plan management and support coordination, asset management, and related financial products and services.

    The company's asset management businesses provide motor vehicle leasing and fleet management services, as well as fleet and consumer financing.

    McMillan Shakespeare consists of more than 20 subsidiaries, the majority incorporated in Australia but also in New Zealand and the United Kingdom.

    MMS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $14.13 $0.02 0.14% 210,462 $14.25 $14.25 $14.10
    19 Dec 2024 $14.11 $-0.29 -2.01% 207,418 $14.35 $14.35 $14.11
    18 Dec 2024 $14.40 $0.11 0.77% 230,859 $14.37 $14.65 $14.25
    17 Dec 2024 $14.29 $0.25 1.78% 144,725 $14.04 $14.39 $14.03
    16 Dec 2024 $14.04 $-0.60 -4.10% 589,331 $14.60 $14.60 $14.04
    13 Dec 2024 $14.64 $0.34 2.38% 129,024 $14.38 $14.66 $14.33
    12 Dec 2024 $14.30 $-0.31 -2.12% 426,356 $14.50 $14.63 $14.29
    11 Dec 2024 $14.61 $-0.10 -0.68% 240,739 $14.74 $14.86 $14.60
    10 Dec 2024 $14.71 $-0.23 -1.54% 192,300 $14.91 $14.95 $14.71
    09 Dec 2024 $14.94 $-0.13 -0.86% 187,904 $15.12 $15.16 $14.90
    06 Dec 2024 $15.07 $0.06 0.40% 180,557 $15.01 $15.13 $14.90
    05 Dec 2024 $15.01 $0.12 0.81% 414,430 $14.91 $15.28 $14.89
    04 Dec 2024 $14.89 $-0.10 -0.67% 365,815 $14.95 $15.01 $14.82
    03 Dec 2024 $14.99 $0.15 1.01% 140,372 $14.88 $15.03 $14.83
    02 Dec 2024 $14.84 $-0.24 -1.59% 165,290 $15.20 $15.30 $14.84
    29 Nov 2024 $15.08 $-0.04 -0.26% 115,817 $15.06 $15.11 $14.94
    28 Nov 2024 $15.12 $0.22 1.48% 213,840 $14.89 $15.22 $14.85
    27 Nov 2024 $14.90 $-0.05 -0.33% 283,514 $15.00 $15.01 $14.77
    26 Nov 2024 $14.95 $-0.09 -0.60% 389,032 $15.09 $15.09 $14.86
    25 Nov 2024 $15.04 $0.04 0.27% 426,594 $15.22 $15.47 $15.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Dec 2024 Robert (Rob) De Luca Issued 45,608 $687,312
    Director remuneration. 184,931 Performance Rights
    20 Sep 2024 Arlene Tansey Buy 4,500 $67,320
    On-market trade.
    11 Sep 2024 Arlene Tansey Buy 488 $7,690
    On-market trade.
    11 Sep 2024 Robert (Rob) De Luca Buy 8,668 $137,647
    Conversion of securities.
    11 Sep 2024 Robert (Rob) De Luca Exercise 8,668 $137,647
    Conversion of securities. 139,323 Performance Rights
    30 Aug 2024 Arlene Tansey Buy 2,412 $37,675
    On-market trade.
    29 Aug 2024 Kathryn Parsons Buy 1,500 $23,670
    On-market trade.
    27 Aug 2024 Robert (Rob) De Luca Expiry 2,469 $43,528
    As advised by the company. Lapsed, 147,991 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Bruce John Akhurst Non-Executive Director Apr 2021
    Mr Akhurst is currently the Chairman of Tabcorp Holdings Limited and Chair of the Peter McCallum Cancer Foundation. Mr Akhurst was previously the CEO of Sensis, Group MD and General Counsel of Telstra, Partner of Mallesons Stephen Jaques, Council Member of RMIT University and a Director of Vocus Group Limited. Mr Akhurst is considered an independent director under the Company's definition of independence. He is Member of the Risk and Compliance Committee.
    Mr John G Bennetts Non-Executive Director Dec 2003
    Mr Bennetts is an investor and has been the founder and director of several Australian companies. He owns businesses in varied industries including technology and finance. Mr Bennetts is a Non-Executive Director of Sacred Heart Mission. He was a founder of Cellestis Limited and private equity investment firm, Mooroolbark Investments Pty Limited (M-Group). He has also provided corporate advisory services to a range of companies in Australia and Asia. Prior to the establishment of M-Group, he was a senior executive of pioneering Australian multinational IT company, Datacraft Limited.
    Mr Ross Chessari Non-Executive Director Dec 2003
    Mr Chessari is a founder and director of the investment manager, SciVentures Investments Pty Limited (SciVentures). Prior to founding SciVentures, Mr Chessari was the Managing Director of ANZ Asset Management and the General Manager of ANZ Trustees. Mr Chessari has participated in the growth and development of the Company.
    Ms Helen Kurincic Non-Executive DirectorNon-Executive Chairman Sep 2018
    Ms Kurincic has formerly held Board roles across the publicly listed, private, not-for-profit and government sectors including Non-Executive Chair of Integral Diagnostics Limited, Non-Executive Director of Estia Health Limited, insurer HBF Health Limited, Domain Principal Group, DCA Group and Melbourne Health. Past management roles include Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. She is Member of the Risk and Compliance Committee and Member of the People and Culture Committee.
    Ms Arlene May Tansey Non-Executive Director Nov 2022
    Ms Tansey is a Non-Executive Director of TPG Telecom, Aristocrat Leisure Limited, Lendlease Investment Management, and La Trobe Finance. She is also a Board member of the Australian National Maritime Museum and University of Wollongong Global Enterprises. She is formerly Non-Executive Director of WiseTech Global Limited, Infrastructure NSW and the Australian Institute of Company Directors. Before becoming a non-executive Director, Ms Tansey worked in commercial and investment banking in Australia and in investment banking and law in the United States. She is Member of the Risk and Compliance Committee and Member of the People and Culture Committee.
    Mr Robert (Rob) De Luca Chief Executive OfficerManaging Director May 2022
    Mr De Luca has over 20 years of experience in the Financial Services, Wealth Management, Disability and Healthcare sectors, including roles as Managing Director of Bankwest, CEO of the National Disability Insurance Agency (NDIA). Prior to joining MMS, Mr De Luca was CEO of Zenitas Healthcare.
    Ms Kathryn Maree Parsons Non-Executive Director May 2020
    Ms Parsons is currently a Non-Executive Director of Nick Scali Limited and Shape Australia Corporation Limited. She brings to the board finance and risk management experience. Ms Parsons was formerly an audit partner at Ernst & Young where she spent time as a partner in the firm's US, UK and Australian practices. In addition to her audit client responsibilities, she was part of the firm's Oceania Assurance Leadership team as the Professional Practice Director with responsibility for assurance quality and risk management in the region. She is Chair of the Risk and Compliance Committee and Member of the People and Culture Committee.
    Ms Elizabeth Spooner Company Secretary Sep 2024
    -
    Elizabeth Spooner Company Secretary
    -
    A. Conn Group Chief Financial Officer (CFO) and Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Aust) Ltd 14,341,226 20.59%
    Citicorp Nominees Limited 9,659,571 13.87%
    Jp Morgan Nominees Australia Limited 9,055,068 13.00%
    Chessari Holdings Pty Limited 1 6,050,941 8.69%
    AP Group Pty Limited 3,976,229 5.71%
    Asia Pac Technology Pty Ltd 2 3,068,025 4.41%
    UBS Nominees Pty Limited 1,642,741 2.36%
    National Nominees Limited 1,603,815 2.30%
    Ann Leslie Ryan 1,008,418 1.45%
    BNP Paribas Nom Pty Limited 516,216 0.74%
    BNP Paribas Noms Pty Ltd <Agency Lending A/c> 432,139 0.62%
    Bnp Paribas Noms Pty Ltd <Global Markets Drp> 369,772 0.53%
    HSBC Custody Nominees (Australia) Limited <NT Commonwealth Super Corp A/c> 317,722 0.46%
    Neweconomy Com Au Nominees Pty Limited 316,783 0.45%
    MOHL Invest Pty Ltd <MOHL Super Fund A/c> 310,000 0.45%
    Citicorp Nominees Pty Ltd <Colonial First State Inv A/c> 306,624 0.44%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 194,956 0.28%
    Mod Enterprises Pty Ltd 193,139 0.28%
    Birdseye No.2 Management Pty Ltd <Birdseye Super No. 2 Fund A/c> 150,000 0.22%
    Netwealth Investments Limited <Wrap Services A/C> 141,977 0.20%

    Profile

    since

    Note